Skip to main content

Moderna, Inc Value Stock - Dividend - Research Selection

Moderna

ISIN: US60770K1079 , WKN: A2N9D9

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Heard on the Street: Moderna Got a Boost From Bird Flu, but Don’t Count Your Chicks

2024-05-23
Moderna, BioNTech, CureVac and Novavax have added billions of dollars in combined market capitalization gains in recent days after two cases of bird flu were reported in humans in the U.S. and reports emerged of a potential federal government vaccine program. On Wednesday, Moderna gained 14% while BioNTech added 11%. CureVac jumped 19%.

Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

2024-05-23
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.

8 Health Care Stocks Whale Activity In Today's Session

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Moderna Announces Data to be presented at 2024 ASCO Annual Meeting

2024-05-23
CAMBRIDGE - Moderna, Inc. today announced that three abstracts on mRNA-4157 , an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2024 American...

The Moderna News That Has MRNA Stock Price Surging This Week: 3 Key Catalysts

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

The Moderna News That Has MRNA Stock Price Surging: 3 Key Catalysts

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor

2024-05-23
Moderna's stock price is rising on fears of a new infectious disease outbreak, reminiscent of its pandemic gains. Read why I'm neutral on MRNA stock.

Moderna Options Trading: A Deep Dive into Market Sentiment

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wall Street Breakfast Podcast: Nvidia Soars On Strong Earnings, Guidance, And Stock Split

2024-05-23
Nvidia gains as Q1 results, guidance top expectations; announces 10-1 split. Live Nation sinks 7% on report DOJ antitrust action is ready. Moderna, BioNTech close double-digits.

SPY ETF Update, 5/23/2024���

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.